MakGroup Healthcare becomes sole distributor of PixCell Medical's HemoScreen in the UAE

Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East

PixCell Medical, an innovator of rapid haematology testing solutions at the point of care announced that it has signed an exclusive distribution agreement with United MakGroup Technologies to distribute HemoScreen across the United Arab Emirates. PixCell's HemoScreen delivers lab-accurate diagnostic information from a single finger-prick of blood within five minutes, facilitating rapid and reliable clinical decision-making supported by real-time diagnostic data.

Headquartered in Dubai, MakGroup Healthcare is a leading distributor of medical devices across the Middle East, providing access to advanced technological solutions for applications in laboratory, radiology and cardiology settings. With no existing reliable and efficient solutions for point-of-care (POC) diagnostic testing in the region, the company is expanding its product portfolio to distribute PixCell's HemoScreen, the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for POC use.

"Providing cost-effective and smart medical device solutions is central to our mission, and PixCell brings a unique offering to the market – an exceptionally simple, portable and miniaturized CBC analyzer that offers critical results when they are needed most," said Zahir Ali, Director of Healthcare at MakGroup Healthcare. "The importance of improving access to care has become increasingly evident. Point-of-care diagnostics allow for enhanced clinical decision-making and reduced turnaround time, and we are confident that this partnership with PixCell will support us in delivering a rapid solution for the world's most common blood test to improve access to quality healthcare in the Middle East."

Utilizing a patented, disposable cartridge preloaded with all necessary reagents, HemoScreen reduces reagent waste and eliminates the need for device maintenance and calibration. Designed for ease of use by non-technical operators, HemoScreen provides CBC results as well as comprehensive abnormal cell flagging for earlier detection of infection and certain cancer types. PixCell's goal is to increase access to CBC blood testing to improve patient care and outcomes.

"As society pivots to a wider adoption of point-of-care diagnostic testing, we are proud to be at the forefront of this healthcare revolution, adding another HemoScreen distribution deal to our growing list of partnerships," said Dr. Avishay Bransky, co-founder and CEO of PixCell Medical. "We are proud to collaborate with a leading and trusted provider of healthcare solutions, a company known for its uncompromising quality. We are confident that MakGroup Healthcare will serve as an excellent partner and help to dramatically improve the accessibility of the CBC, the most essential blood test, within the markets it serves."